Feature | February 27, 2013

Oncology Information Systems' Reporting and Alerts Leave Providers Wanting More

As meaningful use and ACOs pick up steam, oncology providers contend with regulatory pressures with or without help from their vendors

Oncology Information Management Systems KLAS Meaningful Use Reports Alert

February 27, 2013 — Alerts and reporting are two of the most challenging aspects of medical oncology, in addition to being the tools providers are least happy with overall. This is according to a new report from KLAS titled Oncology 2012: Pulling the Curtain Back.

Study findings reveal that oncology information system vendors struggle with alerts. Specifically, Epic, Varian and Elekta seem to perform below average. Reporting is also an area for improvement. Providers report that Varian and Elekta's canned reports are not robust enough to meet their needs, and the customized reports are difficult to use. Epic's customized reports are not as user friendly as providers would like them to be.

Meaningful use (MU) is another hot button for providers. The vast majority of oncology providers interviewed indicate that they are planning to attest for MU, but according to the report, vendors differ in their ability to partner with providers in that effort. Altos and BMSi are the best reported MU partners because they are more hands on and appear to be more focused on customer needs.

Though Varian is one of the dominant players in the oncology IT market, the report indicates that they are not the best MU partner. The MU version of Varian ARIA did not come out on the promised timeline, and some providers report that Varian seems out of touch with customers. Additionally, Epic is identified as a vendor that could improve due to the fact that the system is not designed for all the needs of oncology providers.

With MU Stage 2 bearing down, patient portals are also identified as an important consideration for oncology providers. Only 30 percent of those surveyed said they are currently using a patient portal, and many still need to make that decision.

"Most of the Epic and Altos customers in the study said they are using patient portals; however, we spoke with only a small number of those customers," said Monique Rasband, oncology research director and author of the report. "The majority of Elekta and Varian customers have not yet adopted a portal. Most Varian and Elekta customers said they are looking to their current oncology IT vendor to supply a portal, in spite of most portals being rudimentary at this point."

This study includes ratings on medical and radiation oncology IS vendors. Vendors rated in radiation oncology are BMSi, Elekta and Varian. Vendors rated in medical oncology are Altos (early data), Elekta, Epic, IntrinsiQ and Varian. To learn more about the oncology IS market and the vendors in this study, providers and vendors can review the full report Oncology IT: Pulling the Curtain Back. This report is available to healthcare providers at a significant discount.

For more information: www.KLASresearch.com/KLASreports

Related Content

New Module Creates a Warped MRI Scan that Matches Real-Time Ultrasound Results (Graphic: Business Wire)

New Module Creates a Warped MRI Scan that Matches Real-Time Ultrasound Results (Graphic: Business Wire)

News | Artificial Intelligence | May 07, 2021
News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
With the growing adoption of #data #analytics in #healthcare, we are seeing more clearly that there are two sides of data
Feature | Artificial Intelligence | May 05, 2021 | By Sundararajan Mani
With the growing adoption of...
As key technological advancements become more pronounced, prolific developments are anticipated to be on the future horizon

Getty Images

Feature | Teleradiology | May 05, 2021 | By Abizer Shaikhmahmud
Teleradiology is grabbing significant eyeballs,
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
The promise of personalized medicine, with its potential for treatments tailored to individual patients’ genomic footprints to generate better outcomes, has long tantalized the life sciences industry

Image courtesy of HealthMyne

Feature | Information Technology | May 04, 2021 | By Rose Higgins
The promise of...